Icure Pharmaceutical Incorporation (175250) - Total Liabilities

Latest as of June 2025: ₩80.55 Billion KRW ≈ $54.59 Million USD

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW (≈ $54.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Icure Pharmaceutical Incorporation (175250) equity growth momentum to track the company's year-over-year net asset growth rate.

Icure Pharmaceutical Incorporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. See 175250 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Icure Pharmaceutical Incorporation Competitors by Total Liabilities

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.

Company Country Total Liabilities
Fortune Minerals Limited
TO:FT
Canada CA$17.76 Million
NTPM Holdings Bhd
KLSE:5066
Malaysia RM484.30 Million
American Creek Resources Ltd
V:AMK
Canada CA$30.45K
Jiayin Group Inc
NASDAQ:JFIN
USA $4.32 Billion
Samhwa Networks Co. Ltd
KQ:046390
Korea ₩38.95 Billion
Playstudios Inc
NASDAQ:MYPS
USA $60.23 Million
Flag Ship Acquisition Corp. Ordinary Shares
NASDAQ:FSHP
USA $2.93 Million
Fidelix Co. Ltd
KQ:032580
Korea ₩11.13 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Icure Pharmaceutical Incorporation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.71 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.62 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 ₩72.62 Billion
≈ $49.22 Million
-31.84%
2023-12-31 ₩106.54 Billion
≈ $72.20 Million
-20.76%
2022-12-31 ₩134.45 Billion
≈ $91.11 Million
+12.33%
2021-12-31 ₩119.69 Billion
≈ $81.11 Million
+44.22%
2020-12-31 ₩82.99 Billion
≈ $56.24 Million
-29.82%
2019-12-31 ₩118.27 Billion
≈ $80.15 Million
+225.73%
2018-12-31 ₩36.31 Billion
≈ $24.61 Million
-0.32%
2017-12-31 ₩36.43 Billion
≈ $24.69 Million
+149.76%
2016-12-31 ₩14.58 Billion
≈ $9.88 Million
-27.76%
2015-12-31 ₩20.19 Billion
≈ $13.68 Million
--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$54.96 Million
₩81.09 Billion KRW
Market Cap Rank
#21486 Global
#1236 in Korea
Share Price
₩2170.00
Change (1 day)
+0.00%
52-Week Range
₩2170.00 - ₩2170.00
All Time High
₩23730.97
About

Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more